My Bibliography

select

Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Mol Oncol. 2022 Jun;16(11):2117-2134. doi: 10.1002/1878-0261.13146. Epub 2022 Jan 4. Review. PubMed PMID: 34854206; PubMed Central PMCID: PMC9168966.

select

Fourquet A, Rosenberg A, Mena E, Shih JJ, Turkbey B, Blain M, Bergvall E, Lin F, Adler S, Lim I, Madan RA, Karzai F, Gulley JL, Dahut WL, Wood BJ, Chang R, Levy E, Choyke PL, Lindenberg L. A Comparison of (18)F-DCFPyL, (18)F-NaF, and (18)F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer. J Nucl Med. 2022 May;63(5):735-741. doi: 10.2967/jnumed.121.262371. Epub 2021 Sep 2. PubMed PMID: 34475237.

select

Hrinczenko B, Iannotti N, Goel S, Spigel D, Safran H, Taylor MH, Bennouna J, Wong DJ, Kelly K, Verschraegen C, Bajars M, Manitz J, Ruisi M, Gulley JL. Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor. Future Oncol. 2022 Apr;18(11):1333-1342. doi: 10.2217/fon-2021-0930. Epub 2022 Feb 11. PubMed PMID: 35144482; PubMed Central PMCID: PMC9066292.

select

Bilusic M, Toney NJ, Donahue RN, Wroblewski S, Zibelman M, Ghatalia P, Ross EA, Karzai F, Madan RA, Dahut WL, Gulley JL, Schlom J, Plimack ER, Geynisman DM. A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer Prostatic Dis. 2022 Apr;25(4):735-740. doi: 10.1038/s41391-022-00492-y. Epub 2022 Jan 25. PubMed PMID: 35079115; PubMed Central PMCID: PMC9309187.

select

Goswami M, Gui G, Dillon LW, Lindblad KE, Thompson J, Valdez J, Kim DY, Ghannam JY, Oetjen KA, Destefano CB, Smith DM, Tekleab H, Li Y, Dagur P, Hughes T, Marté JL, Del Rivero J, Klubo-Gwiezdzinksa J, Gulley JL, Calvo KR, Lai C, Hourigan CS. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003392. PubMed PMID: 35017151; PubMed Central PMCID: PMC8753450.

select

Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 9. PubMed PMID: 34895481; PubMed Central PMCID: PMC8742225.

select

Wilkinson S, Ye H, Karzai F, Harmon SA, Terrigino NT, VanderWeele DJ, Bright JR, Atway R, Trostel SY, Carrabba NV, Whitlock NC, Walker SM, Lis RT, Abdul Sater H, Capaldo BJ, Madan RA, Gulley JL, Chun G, Merino MJ, Pinto PA, Salles DC, Kaur HB, Lotan TL, Venzon DJ, Choyke PL, Turkbey B, Dahut WL, Sowalsky AG. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. 2021 Dec;80(6):746-757. doi: 10.1016/j.eururo.2021.03.009. Epub 2021 Mar 27. PubMed PMID: 33785256; PubMed Central PMCID: PMC8473585.

select

Chau V, Madan RA, Bilusic M, Owens H, Cordes LM, Marte JL, Gulley JL, Lee JM, Dahut WL, Karzai F. Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations. Clin Genitourin Cancer. 2021 Dec;19(6):e352-e359. doi: 10.1016/j.clgc.2021.05.005. Epub 2021 May 17. PubMed PMID: 34116956; PubMed Central PMCID: PMC9595034.

select

Palena C, Gulley JL. A rare insight into the immunosuppressive landscape of prostate cancer bone metastases. Cancer Cell. 2021 Nov 8;39(11):1450-1452. doi: 10.1016/j.ccell.2021.09.004. Epub 2021 Nov 8. PubMed PMID: 34752752; PubMed Central PMCID: PMC9563857.

select

DeMaria PJ, Lee-Wisdom K, Donahue RN, Madan RA, Karzai F, Schwab A, Palena C, Jochems C, Floudas C, Strauss J, Marté JL, Redman JM, Dombi E, Widemann B, Korchin B, Adams T, Pico-Navarro C, Heery C, Schlom J, Gulley JL, Bilusic M. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-003238. PubMed PMID: 34479925; PubMed Central PMCID: PMC8420671.

select

Robbins Y, Friedman J, Clavijo PE, Sievers C, Bai K, Donahue RN, Schlom J, Sinkoe A, Hinrichs CS, Allen C, Abdul Sater H, Gulley JL, Norberg S. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis. J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-003113. PubMed PMID: 34462327; PubMed Central PMCID: PMC8407210.

select

Bilusic M, Gulley JL. Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?. J Natl Cancer Inst. 2021 Jul 1;113(7):799-800. doi: 10.1093/jnci/djaa217. PubMed PMID: 33432346; PubMed Central PMCID: PMC8246798.

select

Reimann H, Nguyen A, Sanborn JZ, Vaske CJ, Benz SC, Niazi K, Rabizadeh S, Spilman P, Mackensen A, Ruebner M, Hein A, Beckmann MW, van der Meijden ED, Bausenwein J, Kretschmann S, Griffioen M, Schlom J, Gulley JL, Lee KL, Hamilton DH, Soon-Shiong P, Fasching PA, Kremer AN. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002605. PubMed PMID: 34172517; PubMed Central PMCID: PMC8237736.

select

DeMaria PJ, Bilusic M, Park DM, Heery CR, Donahue RN, Madan RA, Bagheri MH, Strauss J, Shen V, Marté JL, Steinberg SM, Schlom J, Gilbert MR, Gulley JL. Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. Oncologist. 2021 May;26(5):e847-e858. doi: 10.1002/onco.13720. Epub 2021 Mar 9. PubMed PMID: 33594772; PubMed Central PMCID: PMC8100546.

select

Masoudi S, Mehralivand S, Harmon SA, Lay N, Lindenberg L, Mena E, Pinto PA, Citrin DE, Gulley JL, Wood BJ, Dahut WL, Madan RA, Bagci U, Choyke PL, Turkbey B. Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. IEEE Access. 2021;9:87531-87542. doi: 10.1109/access.2021.3074051. Epub 2021 Apr 20. PubMed PMID: 34733603; PubMed Central PMCID: PMC8562651.

select

Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. BJU Int. 2021 Apr;127(4):435-444. doi: 10.1111/bju.15227. Epub 2020 Oct 23. PubMed PMID: 32969563; PubMed Central PMCID: PMC8265825.

select

Gatti-Mays ME, Gameiro SR, Ozawa Y, Knudson KM, Hicks KC, Palena C, Cordes LM, Steinberg SM, Francis D, Karzai F, Lipkowitz S, Donahue RN, Jochems C, Schlom J, Gulley JL. Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. Front Oncol. 2020;10:581801. doi: 10.3389/fonc.2020.581801. eCollection 2020. PubMed PMID: 33747894; PubMed Central PMCID: PMC7977003.

select

Chalfin HJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, Chu YL, Richardson R, Krupa R, Anderson AKL, Wang Y, Dittamore R, Pal SK, Lara PN, Stein MN, Quinn DI, Steinberg SM, Cordes LM, Ley L, Mallek M, Sierra Ortiz O, Costello R, Cadena J, Diaz C, Gulley JL, Dahut WL, Streicher H, Wright JJ, Trepel JB, Bottaro DP, Apolo AB. Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. Clin Cancer Res. 2021 Mar 1;27(5):1391-1398. doi: 10.1158/1078-0432.CCR-20-2891. Epub 2020 Dec 1. PubMed PMID: 33262136; PubMed Central PMCID: PMC7925349.

select

Bilusic M, McMahon S, Madan RA, Karzai F, Tsai YT, Donahue RN, Palena C, Jochems C, Marté JL, Floudas C, Strauss J, Redman J, Abdul Sater H, Rabizadeh S, Soon-Shiong P, Schlom J, Gulley JL. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2021-002374. PubMed PMID: 33762322; PubMed Central PMCID: PMC7993215.

select

Donahue RN, Marté JL, Goswami M, Toney NJ, Tsai YT, Gulley JL, Schlom J. Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002087. Review. PubMed PMID: 33707314; PubMed Central PMCID: PMC7956734.

select

Madan RA, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner II, Singh H, Arlen PM, Theoret MR, Marté JL, Cordes L, Couvillon A, Hankin A, Williams M, Owens H, Lochrin SE, Chau CH, Steinberg S, Figg WD, Dahut W, Schlom J, Gulley JL. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001556. PubMed PMID: 33664086; PubMed Central PMCID: PMC7934713.

select

Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, Ambinder R, Cheever M, Gulley JL, Goncalves PH, Wang HW, Uldrick TS, Yarchoan R. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-002097. PubMed PMID: 33608378; PubMed Central PMCID: PMC7898875.

select

Gatti-Mays M, Gulley JL. Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis. J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-002252. PubMed PMID: 33602697; PubMed Central PMCID: PMC7896600.

select

Karzai F, Walker SM, Wilkinson S, Madan RA, Shih JH, Merino MJ, Harmon SA, VanderWeele DJ, Cordes LM, Carrabba NV, Bright JR, Terrigino NT, Chun G, Bilusic M, Couvillon A, Hankin A, Williams MN, Lis RT, Ye H, Choyke PL, Gulley JL, Sowalsky AG, Turkbey B, Pinto PA, Dahut WL. Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. Clin Cancer Res. 2021 Jan 15;27(2):429-437. doi: 10.1158/1078-0432.CCR-20-2344. Epub 2020 Oct 6. PubMed PMID: 33023952; PubMed Central PMCID: PMC7855232.

select

Yu G, Butler MK, Abdelmaksoud A, Pang Y, Su YT, Rae Z, Dadkhah K, Kelly MC, Song YK, Wei JS, Terabe M, Atony R, Mentges K, Theeler BJ, Penas-Prado M, Butman J, Camphausen K, Zaghloul KA, Nduom E, Quezado M, Aldape K, Armstrong TS, Gilbert MR, Gulley JL, Khan J, Wu J. Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. Front Oncol. 2020;10:601452. doi: 10.3389/fonc.2020.601452. eCollection 2020. PubMed PMID: 33520712; PubMed Central PMCID: PMC7841290.

select

Gubbi S, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL, Del Rivero J. In Reply. Oncologist. 2021 Jan;26(1):e192-e193. doi: 10.1002/onco.13589. Epub 2020 Nov 23. PubMed PMID: 33150998; PubMed Central PMCID: PMC7794181.

select

Salkeni MA, Shin JY, Gulley JL. Resistance to Immunotherapy: Mechanisms and Means for Overcoming. Adv Exp Med Biol. 2021;1342:45-80. doi: 10.1007/978-3-030-79308-1_2. PubMed PMID: 34972962.

select

Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E, Redman JM, Sater HA, Donahue RN, Jochems C, Lamping E, Burmeister A, Marté JL, Cordes LM, Bilusic M, Karzai F, Ojalvo LS, Jehl G, Rolfe PA, Hinrichs CS, Madan RA, Schlom J, Gulley JL. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001395. PubMed PMID: 33323462; PubMed Central PMCID: PMC7745517.

select

Naing A, Hajjar J, Gulley JL, Atkins MB, Ciliberto G, Meric-Bernstam F, Hwu P. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001754. PubMed PMID: 33310772; PubMed Central PMCID: PMC7735083.

select

Pastor DM, Lee-Wisdom K, Arai AE, Sirajuddin A, Rosing DR, Korchin B, Gulley JL, Bilusic M. Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report. Front Oncol. 2020;10:603248. doi: 10.3389/fonc.2020.603248. eCollection 2020. PubMed PMID: 33330104; PubMed Central PMCID: PMC7717959.

select

Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, Figg WD, Gulley JL, Agarwal PK, Valera V, Chalfin HJ, Jones J, Streicher H, Wright JJ, Ning YM, Parnes HL, Dahut WL, Bottaro DP, Lara PN Jr, Saraiya B, Pal SK, Stein MN, Mortazavi A. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 Nov 1;38(31):3672-3684. doi: 10.1200/JCO.20.01652. Epub 2020 Sep 11. PubMed PMID: 32915679; PubMed Central PMCID: PMC7605393.

select

Kelly K, Manitz J, Patel MR, D'Angelo SP, Apolo AB, Rajan A, Kasturi V, Speit I, Bajars M, Warth J, Gulley JL. Efficacy and immune-related adverse event associations in avelumab-treated patients. J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001427. PubMed PMID: 33219092; PubMed Central PMCID: PMC7682456.

select

Bilusic M, Einstein DJ, Karzai FH, Dahut WL, Gulley JL, Aragon-Ching JB, Madan RA. The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. Urol Clin North Am. 2020 Nov;47(4):457-467. doi: 10.1016/j.ucl.2020.07.004. Review. PubMed PMID: 33008496; PubMed Central PMCID: PMC8177734.

select

Marté JL, Toney NJ, Cordes L, Schlom J, Donahue RN, Gulley JL. Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management. J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001019. PubMed PMID: 33219091; PubMed Central PMCID: PMC7681794.

select

Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, Gourdin T, Dirix L, Lee KW, Taylor MH, Schöffski P, Wang D, Ravaud A, Manitz J, Pennock G, Ruisi M, Gulley JL, Patel MR. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001246. PubMed PMID: 33037118; PubMed Central PMCID: PMC7549450.

select

Verschraegen CF, Jerusalem G, McClay EF, Iannotti N, Redfern CH, Bennouna J, Chen FL, Kelly K, Mehnert J, Morris JC, Taylor M, Spigel D, Wang D, Grote HJ, Zhou D, Munshi N, Bajars M, Gulley JL. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. J Immunother Cancer. 2020 Sep;8(2). doi: 10.1136/jitc-2020-001064. PubMed PMID: 32907924; PubMed Central PMCID: PMC7481079.

select

Joseph JJ, Rajan A, Gulley JL, Ito S, Kessler CM. Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation. JTO Clin Res Rep. 2020 Sep;1(3):100049. doi: 10.1016/j.jtocrr.2020.100049. eCollection 2020 Sep. PubMed PMID: 34589945; PubMed Central PMCID: PMC8474288.

select

Del Rivero J, Donahue RN, Marté JL, Gramza AW, Bilusic M, Rauckhorst M, Cordes L, Merino MJ, Dahut WL, Schlom J, Gulley JL, Madan RA. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. Front Endocrinol (Lausanne). 2020;11:490. doi: 10.3389/fendo.2020.00490. eCollection 2020. PubMed PMID: 32849281; PubMed Central PMCID: PMC7427000.

select

Apolo AB, Nadal R, Tomita Y, Davarpanah NN, Cordes LM, Steinberg SM, Cao L, Parnes HL, Costello R, Merino MJ, Folio LR, Lindenberg L, Raffeld M, Lin J, Lee MJ, Lee S, Alarcon SV, Yuno A, Dawson NA, Allette K, Roy A, De Silva D, Lee MM, Sissung TM, Figg WD, Agarwal PK, Wright JJ, Ning YM, Gulley JL, Dahut WL, Bottaro DP, Trepel JB. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 2020 Aug;21(8):1099-1109. doi: 10.1016/S1470-2045(20)30202-3. Epub 2020 Jul 6. PubMed PMID: 32645282; PubMed Central PMCID: PMC8236112.

select

Madan RA, Schmidt KT, Karzai F, Peer CJ, Cordes LM, Chau CH, Steinberg SM, Owens H, Eisner J, Moore WR, Dahut WL, Gulley JL, Figg WD. Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. Clin Genitourin Cancer. 2020 Aug;18(4):258-267.e1. doi: 10.1016/j.clgc.2019.11.002. Epub 2020 Mar 29. PubMed PMID: 32327394; PubMed Central PMCID: PMC7415516.

select

Robbins Y, Greene S, Friedman J, Clavijo PE, Van Waes C, Fabian KP, Padget MR, Abdul Sater H, Lee JH, Soon-Shiong P, Gulley J, Schlom J, Hodge JW, Allen CT. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. Elife. 2020 Jul 7;9. doi: 10.7554/eLife.54854. PubMed PMID: 32633234; PubMed Central PMCID: PMC7340502.

select

Paz-Ares L, Kim TM, Vicente D, Felip E, Lee DH, Lee KH, Lin CC, Flor MJ, Di Nicola M, Alvarez RM, Dussault I, Helwig C, Ojalvo LS, Gulley JL, Cho BC. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222. doi: 10.1016/j.jtho.2020.03.003. Epub 2020 Mar 13. PubMed PMID: 32173464; PubMed Central PMCID: PMC8210474.

select

Collins JM, Donahue RN, Tsai YT, Manu M, Palena C, Gatti-Mays ME, Marté JL, Madan RA, Karzai F, Heery CR, Strauss J, Abdul-Sater H, Cordes L, Schlom J, Gulley JL, Bilusic M. Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. Oncologist. 2020 Jul;25(7):560-e1006. doi: 10.1634/theoncologist.2019-0932. Epub 2019 Dec 26. PubMed PMID: 31876334; PubMed Central PMCID: PMC7356719.

select

Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, Awada A, Borel C, Ojalvo LS, Helwig C, Rolfe PA, Gulley JL, Penel N. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000664. PubMed PMID: 32641320; PubMed Central PMCID: PMC7342865.

select

Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. J Natl Cancer Inst. 2020 Jun 1;112(6):562-573. doi: 10.1093/jnci/djaa021. Review. PubMed PMID: 32145020; PubMed Central PMCID: PMC7301097.

select

Gatti-Mays ME, Redman JM, Donahue RN, Palena C, Madan RA, Karzai F, Bilusic M, Sater HA, Marté JL, Cordes LM, McMahon S, Steinberg SM, Orpia A, Burmeister A, Schlom J, Gulley JL, Strauss J. A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. Oncologist. 2020 Jun;25(6):479-e899. doi: 10.1634/theoncologist.2019-0608. Epub 2019 Oct 8. PubMed PMID: 31594913; PubMed Central PMCID: PMC7288633.

select

Portal DE, Weiss RE, Wojtowicz M, Mansour A, Monken C, Mehnert JM, Aisner JA, Kane M, Nishioka J, Aisner S, Peters S, Stein MN, Kim IY, Mayer TM, Shih W, Gulley J, Streicher H, Singer EA, Lattime EC. Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. Cancer Gene Ther. 2020 Jun;27(6):438-447. doi: 10.1038/s41417-019-0112-z. Epub 2019 Jun 20. PubMed PMID: 31222182; PubMed Central PMCID: PMC6923616.

select

Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2020-000878. PubMed PMID: 32300051; PubMed Central PMCID: PMC7204613.

select

Del Rivero J, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. Oncologist. 2020 Apr;25(4):290-300. doi: 10.1634/theoncologist.2018-0470. Epub 2019 Oct 10. PubMed PMID: 32297436; PubMed Central PMCID: PMC7160393.

select

Jadvar H, Ballas LK, Choyke PL, Fanti S, Gulley JL, Herrmann K, Hope TA, Klitzke AK, Oldan JD, Pomper MG, Rowe SP, Subramaniam RM, Taneja SS, Vargas HA, Ahuja S. Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. J Nucl Med. 2020 Apr;61(4):552-562. doi: 10.2967/jnumed.119.240929. PubMed PMID: 32238495.